Paper Details

  1. Home
  2. Paper Details

Dalfampridine in patients with downbeat nystagmus--an observational study.

Author: BardinsStanislav, ClaassenJens, FeilKatharina, JahnKlaus, KallaRoger, SchneiderErich, SchnieppRoman, SpiegelRainer, StruppMichael, TeufelJulian

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study investigated the effects of dalfampridine, a medication for downbeat nystagmus (DBN), on slow phase velocity (SPV) and visual acuity (VA). It found that dalfampridine significantly reduced SPV and improved VA, with a good tolerance profile.
Paper Details　
Original Abstract of the Article :
We investigated the effects of dalfampridine, the sustained-release form of 4-aminopyridine, on slow phase velocity (SPV) and visual acuity (VA) in patients with downbeat nystagmus (DBN) and the side effects of the drug. In this proof-of-principle observational study, ten patients received dalfampri...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s00415-013-6911-5

データ提供：米国国立医学図書館（NLM）

Dalfampridine: A New Hope for Downbeat Nystagmus?

Downbeat nystagmus (DBN) is a rare neurological condition causing involuntary eye movements. This observational study investigated the effects of dalfampridine, a drug used to treat multiple sclerosis, on reducing slow phase velocity (SPV) and improving visual acuity (VA) in patients with DBN. The study aimed to evaluate the potential of dalfampridine as a therapeutic option for DBN.

Dalfampridine Shows Promise in Reducing Downbeat Nystagmus

The study found that dalfampridine significantly reduced SPV and improved VA in patients with DBN. The results suggest that dalfampridine may be an effective treatment for DBN, providing relief from the debilitating symptoms associated with this condition. However, the study was small and further research is needed to confirm these findings.

A Potential New Treatment for Downbeat Nystagmus

This study highlights the potential of dalfampridine as a new treatment option for DBN. The drug's effectiveness in reducing SPV and improving VA suggests that it could be a valuable tool in managing this neurological condition. However, as with any new treatment, more research is needed to fully understand its benefits and risks.

Dr. Camel's Conclusion

This observational study provides promising evidence for the potential of dalfampridine in treating DBN. The drug's ability to reduce SPV and improve VA suggests that it could offer a valuable therapeutic option for patients with this rare condition. It underscores the need for further research to confirm its efficacy and explore its long-term effects.

Date :
  1. Date Completed 2014-02-28
  2. Date Revised 2021-10-21
Further Info :

Pubmed ID

23589193

DOI: Digital Object Identifier

10.1007/s00415-013-6911-5

Related Literature

Article Analysis
・Side Effects of dalfampridine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.